Kura’s Darlifarnib Is Chasing a KRAS Crown No One Has Yet Claimed — But the Combination Math Is Harder Than It Looks
Kura Oncology's darlifarnib shows a 44% ORR in ccRCC and targets multiple KRAS mutations. Can it outflank sotorasib and...
KRAS inhibitors